MetaCap

Latigo Biotherapeutics (LTGO) vs Pharming Group N.V. (PHAR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Latigo Biotherapeutics is the larger company by market cap ($861.9 million vs $816.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LTGO-28.77%PHAR+5.39%
+40%+3%-34%
Aug 7, 20261 yearNov 20, 2026
LTGO-28.77%PHAR+5.39%
+36%+1%-34%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LTGO versus PHAR key metrics
MetricLTGOPHAR
Share price$13.00$11.54
Market cap$861.89M$816.78M
1-day change-1.81%-5.10%
YTD return—-34.69%
1-year return—-29.03%
5-year return—+39.04%
P/E ratio (TTM)—36.06
Forward P/E—64.11
EPS (TTM)$-6.07$0.32
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$376.13M
Revenue growth (YoY)—+26.56%
Net income (latest FY)—$2.85M
Gross margin—87.90%
Operating margin—6.87%
Net margin—0.76%
52-week high$25.93$21.34
52-week low$10.24$9.11
Distance from 52-week high-49.87%-45.92%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+301.92%+209.36%
Average volume309.60K21.33K
Shares outstanding66.30M70.78M
Employees66407
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Latigo Biotherapeutics

LTGO stock →

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

About Pharming Group N.V.

PHAR stock →

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 407 employees

LTGO vs PHAR FAQ

Which is bigger, Latigo Biotherapeutics or Pharming Group N.V.?

Latigo Biotherapeutics (LTGO) is larger, with a market capitalization of $861.89M compared with $816.78M for Pharming Group N.V. (PHAR).

Are Latigo Biotherapeutics and Pharming Group N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons